CATX logo

CATX
Perspective Therapeutics Inc

16,351
Mkt Cap
$428.81M
Volume
491,089.00
52W High
$6.16
52W Low
$1.96
PE Ratio
-2.69
CATX Fundamentals
Price
$3.72
Prev Close
$3.76
Open
$3.76
50D MA
$4.32
Beta
1.53
Avg. Volume
1.17M
EPS (Annual)
-$1.40
P/B
1.23
Rev/Employee
$5,325.30
$61.50
Loading...
Loading...
News
all
press releases
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
More News
News Placeholder
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued...
PR Newswire·3mo ago
News Placeholder
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...
PR Newswire·4mo ago
News Placeholder
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +46.96% and +21.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9mo ago
News Placeholder
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -9.38% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10mo ago
News Placeholder
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10mo ago
<
...
1
>

Latest CATX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.